Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.

Details

Language :

English

ISSN :

01615505

Volume :

61

Issue :

7

Database :

Complementary Index

Journal :

Journal of Nuclear Medicine

Publication Type :

Academic Journal

Accession number :

144418060

Full Text :

https://doi.org/10.2967/jnumed.120.245803